FDCP
MRNA icon

Foster Dykema Cabot & Partners’s Moderna MRNA Stock Holding History

Foster Dykema Cabot & Partners’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$700 Hold
10
– – ﹤0.01% 313
2026
Q1 		$508 Hold
10
– – ﹤0.01% 316
2025
Q4 		$295 Hold
10
– – ﹤0.01% 325
2025
Q3 		$258 Hold
10
– – ﹤0.01% 413
2025
Q2 		$276 Hold
10
– – ﹤0.01% 335
2025
Q1 		$284 Hold
10
– – ﹤0.01% 332
2024
Q4 		$416 Hold
10
– – ﹤0.01% 367
2024
Q3 		$668 Hold
10
– – ﹤0.01% 485
2024
Q2 		$1.19K Hold
10
– – ﹤0.01% 305
2024
Q1 		$1.07K Hold
10
– – ﹤0.01% 308
2023
Q4 		$995 Buy
+10
New +$841 ﹤0.01% 254

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Foster Dykema Cabot & Partners's MRNA Position: Q2 2026 in Review

Foster Dykema Cabot & Partners held its Moderna (MRNA) position steady in Q2 2026 at 10 shares worth $700. The position accounts for ﹤0.01% of the portfolio, ranked #313.

Foster Dykema Cabot & Partners first reported a position in MRNA in Q4 2023 and has held it in 11 quarters since. The position peaked at $1.19K in Q2 2024. 784 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • Foster Dykema Cabot & Partners held 10 shares of Moderna worth $700 as of Q2 2026.
  • Foster Dykema Cabot & Partners left its Moderna share count unchanged in Q2 2026.
  • Moderna made up ﹤0.01% of Foster Dykema Cabot & Partners's portfolio in Q2 2026, its #313 holding.
  • Foster Dykema Cabot & Partners first reported a position in Moderna in Q4 2023 and has held it in 11 quarters since.
  • Foster Dykema Cabot & Partners's Moderna position peaked at $1.19K in Q2 2024.
  • 784 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Foster Dykema Cabot & Partners's 13F filing for Q2 2026, filed 11 Aug 2026.